ArticleEuropean journal of medical research2025
Adverse events of special interest after vaccination with COVID-19 vaccines: a cohort event monitoring study in Iran.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety of sinopharm COVID-19 vaccine in children and adolescents aged 5 to 18 years: a cohort event monitoring study.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeThis study aimed to investigate the cumulative incidence of adverse events of special interest (AESI) among Iranians who were vaccinated with COVID-19 vaccines, including Sinopharm, Sputnik V, AZD1222, and COVIran Barekat.
methodsUsing World Health Organization guidelines, this cohort event monitoring (CEM) study was conducted to assess the adverse events of COVID-19 vaccines, in seven cities in Iran. A total of 89783 participants (31690 Sinopharm, 20195 Sputnik V, 23780 AZD1222, and 14118 CoVIran Barekat) who were 18 or older were followed up for 17 weeks (25 weeks for AZD1222) after receiving the first dose of vaccine by weekly phone contacts or self-reporting in a web application. Furthermore, all hospitalized cases were investigated for causes of admission by classification committees.
resultsA total of 11 cases (cumulative incidence: 12.3 per 100,000) of AESIs were recorded. All of the AESI cases were observed among 2080 hospitalized cases. The AESIs included five cases of coagulation disorders (three after AZD1222 and two after Sinopharm vaccination), and three cases of generalized seizure (one after Sputnik V, and two cases after AZD1222). In addition, two cases of Guillain-Barre syndrome, and Sub-acute Thyroiditis were detected after receiving Sputnik V, and one individual developed pericarditis after receiving COVIran Barekat.
conclusionWe found around one AESI among every 8,000 vaccinated Iranian people. The incidence of AESIs after COVID-19 vaccines was relatively rare and the studied vaccines can be considered safe. AZD1222 had a higher incidence of AESIs. Coagulation disorders, and generalized seizure were the main and most common AESIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.